The European Parliament's SANT committee voted at second reading on November 10, 2026 to endorse the negotiated text of the EU pharmaceutical reform directive (procedure 2023/0132(COD)), repealing Directive 2001/83/EC, ahead of the indicative plenary sitting on November 23, 2026. The vote locks the text agreed in second-reading interinstitutional negotiations, the largest overhaul of EU medicines rules in over two decades.
No compliance date is set: the directive is not adopted until the plenary vote, Council adoption, signature and Official Journal publication, with entry into force expected in 2026 and a transition to 2028. EU marketing authorisation holders, generics and biosimilars manufacturers, importers and distributors, ATMP developers, e-pharmacies and SME pharmaceutical companies must run a gap analysis against the reformed provisions and build a transition plan for dossiers, labels, reporting scope and budget before the framework applies, or face non-compliance, misaligned data protection strategy, missed launch and pricing deadlines, and penalty exposure under national transposition.
What does the endorsed pharma package directive change for MA holders?
Building on the Commission's April 2023 proposal, the endorsed directive reshapes every layer of the EU medicines framework. Regulatory data protection (RDP) is the exclusivity period during which a marketing authorisation holder's pre-clinical and clinical test data cannot be relied on by generic or biosimilar applicants; the reformed directive sets a minimum of 8 years, combining 6 years of data protection and 2 years of market protection. Holders gain additional protection for launching in all Member States covered by the authorisation (+2 years), meeting an unmet medical need (+6 months) or running comparative clinical trials (+6 months).
Marketing authorisations become valid for an unlimited period by default, removing the routine 5-year renewal. The European Medicines Agency's human-medicines committees are cut from five to two, the Committee for Medicinal Products for Human Use (CHMP) and the Pharmacovigilance Risk Assessment Committee (PRAC), scientific assessment is shortened from 210 to 180 days and the Commission decision from 67 to 46 days. The negotiated text also adds launch and shortage obligations, a strengthened environmental risk assessment, and antimicrobial stewardship rules.
Who is exposed to the reformed EU medicines directive?
The reform reaches every company that places a medicine on the EU market: innovative MA holders, generics and biosimilars manufacturers, importers and distributors, ATMP developers and hospital exemption holders, e-pharmacies and distance sellers, and SME pharmaceutical companies, across the Member States that will transpose it. Obsidian tracks texts under EU pharmaceutical legislation in 21 jurisdictions, as of November 2026.
What should companies prepare before the directive enters into force?
With the text locked by the SANT committee second-reading vote, MA holders can prepare against a known target rather than wait for the Official Journal. The priority actions are:
- Map the regulatory data protection strategy for each EU product against the new 8-year baseline and its launch-linked extensions.
- Re-plan marketing authorisation lifecycle management for unlimited validity, including the pharmacovigilance and renewal processes that replace the routine 5-year renewal.
- Align dossier formats and internal timelines with the 180-day scientific assessment and the 46-day Commission decision.
- Build launch and shortage reporting workflows for the obligations the directive introduces.
- Strengthen environmental risk assessment submissions and antimicrobial stewardship labelling and dispensing practices.
- Budget for the national transposition gap, where Member States will set penalty regimes and pricing and reimbursement timing.
| Step | Date |
|---|---|
| Commission proposal | April 26, 2023 |
| EP first-reading decision | April 10, 2024 |
| Political agreement (trilogue) | December 11, 2025 |
| Council position published | October 1, 2026 |
| SANT committee second-reading vote | November 10, 2026 |
| Indicative plenary sitting (second reading) | November 23, 2026 |
| Expected entry into force | 2026 (after OJ publication) |
| Application after transition | 2028 |
What happens to MA holders that are not ready when the directive applies?
Companies that defer preparation until the Official Journal publication risk a misaligned regulatory data protection strategy, missed launch and pricing or reimbursement deadlines, and penalty exposure under national transposition. The directive's launch and shortage obligations and the strengthened environmental risk assessment take effect with the transition, and an unprepared dossier or supply setup can cost data protection or market exclusivity once the framework applies.
Pricing and reimbursement applications must reach Member States within 12 months of a request, or 24 months for SMEs, a deadline that compounds with the new launch obligations. Early preparation on dossiers, labels and reporting scope is the only way to keep the transition window usable.
Confirm the directive's scope against your EU portfolio, brief regulatory affairs and supply chain teams on the November 23, 2026 plenary step, and track the Official Journal publication and each Member State's transposition deadline. Continuous, per-jurisdiction monitoring surfaces each step of this reform the moment it publishes.
